NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis^® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer

Immunicom, Inc. has been awarded $2 million by the National Cancer Institute (NCI) and National Institutes of Health (NIH) to initiate its first US-based clinical trial at the Baylor College of Medicine in Houston, Texas.

[Immunicom, Inc.]